WEST NILE VIRUS (WNV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Negligible: No measurable losses; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
OVERVIEW
West Nile virus (WNV) is an orthoflavivirus within the family Flaviviridae, first isolated in Uganda in 1937 and now one of the most widely distributed arboviruses globally, encompassing Africa, the Middle East, Europe, Asia, Australasia, and the Americas. WNV emerged in North America in 1999 causing an outbreak in New York City and has since spread throughout the continental United States, Canada, Latin America, and the Caribbean. The virus is maintained in endemic cycles involving ornithophilic Culex mosquitoes and birds, with humans and horses serving as incidental dead-end hosts that can develop severe neurological disease. In pigs, WNV causes subclinical infection with variable, generally low-level viremia of short duration insufficient to sustain transmission cycles. No clinical disease has been observed in experimentally infected pigs, no pig-to-pig transmission has been documented, and maternal infection did not affect fetal development in the single pregnant sow study conducted. Serological evidence confirms natural WNV exposure in domestic and feral pigs across multiple continents, but pigs are considered incidental hosts with minimal or no role in WNV ecology. WNV is an OIE/WOAH-listed disease due to its significant impact on human and equine health.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
WNV is transmitted to humans exclusively through mosquito bites, with no documented foodborne transmission from consumption of pork or other meat products. Humans are dead-end hosts who develop insufficient viremia to infect mosquito vectors. WNV infection in pigs is subclinical and does not result in viral loads in muscle tissue that would create foodborne risk. Despite widespread WNV circulation in the United States since 1999 and serological evidence of pig exposure, no foodborne transmission pathway has been identified or implicated epidemiologically.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
Unlike JEV where pigs serve as amplifying hosts that increase human infection risk, pigs play no meaningful role in WNV transmission to humans. Pigs develop only low-level, short-duration viremia (peak lasting 0.2-1.1 days in experimental studies) insufficient to sustain transmission cycles. No pig-to-pig transmission occurred in experimental settings where infected and naive pigs were housed together, and pigs failed to become infected when fed WNV-infected mice (unlike cats and birds). The primary transmission cycle involves birds and ornithophilic Culex mosquitoes—pigs are incidental dead-end hosts like humans and horses. Occupational exposure to WNV-infected pigs does not pose infection risk to farm workers beyond the baseline environmental mosquito exposure present in any WNV-endemic area.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity
WNV is maintained in transmission cycles involving Culex species mosquitoes (particularly the Culex pipiens complex) and wild birds that operate entirely independently of pig populations or farm-level biosecurity measures. Birds—especially passerine species like house sparrows, blue jays, and common grackles—are the primary vertebrate hosts, while migratory species (storks, other Ciconiiformes) contribute to long-range virus spread. WNV has been isolated from approximately 60 mosquito species, over 300 bird species, and more than 30 non-avian host species in the United States alone. This extraordinarily broad host and vector range means the virus circulates through wildlife-mosquito cycles that farms cannot control through any biosecurity measures. Pig infection occurs incidentally when competent mosquitoes that have fed on infected birds subsequently bite pigs, not through any pig-specific transmission pathway.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
WNV infection in pigs is subclinical—no clinical signs have been observed in experimentally infected animals—so detection depends entirely on laboratory testing rather than clinical recognition. Serological testing is the primary diagnostic approach, with ELISA formats available for screening followed by virus neutralization (PRNT or micro-neutralization) for confirmation. Interpretation must consider cross-reactions with related orthoflaviviruses that may co-circulate regionally: JEV (Australia, Asia), Usutu virus (Europe), SLEV (North America), and MVEV (Australia). Molecular diagnostics including conventional and real-time RT-PCR, RT-LAMP, and RPA assays are available for detecting WNV RNA in clinical specimens. A pan-WNV real-time RT-PCR assay has been developed for detection across all recognized genetic lineages. Virus isolation in Vero cells is possible but requires appropriate biosafety containment. Given the subclinical nature of pig infections, diagnostic testing would typically occur only as part of surveillance activities or research studies rather than clinical investigation.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Negligible: No measurable losses
WNV infection in pigs causes no documented production losses. Experimental infections produced no clinical signs—no fever, respiratory disease, neurological signs, or mortality were observed. A pregnant sow infected during the second trimester showed no effect on fetal development, no abnormal histological features in fetuses, and no viral antigen in fetal CNS tissue. This contrasts sharply with JEV, which causes significant reproductive losses through transplacental infection. Histopathological examination of experimentally infected weaner pigs showed moderate perivascular cuffing in brain and spinal cord (with meningoencephalitis in some animals), but these findings occurred without clinical manifestation—pigs remained healthy throughout observation periods. Serological surveys confirm natural exposure occurs in domestic and feral pig populations, but this subclinical seroconversion does not translate to any measurable economic impact on pig production.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
WNV is an OIE/WOAH-listed disease, but listing reflects its significance for human and equine health rather than swine production impact. The virus has been endemic throughout the United States since 1999 and is now established across the Americas, Europe, Africa, Asia, and Australasia—this widespread distribution means WNV-positive status does not trigger trade restrictions between most trading partners. Pigs are recognized as incidental dead-end hosts with no role in transmission, so WNV seropositivity in swine populations does not generate regulatory concern equivalent to detection in sentinel horses or wild birds used for public health surveillance. Consumer awareness of WNV relates to mosquito-borne human disease risk, not pork safety—there would be no food safety-driven market response. Detection of WNV antibodies in pigs might prompt public health mosquito surveillance activities but would not affect swine movement or trade.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
WNV is a viral pathogen (positive-sense RNA virus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns regardless of disease epidemiology or management approaches.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for WNV infection, and none are needed in pigs given the subclinical nature of infection. Antimicrobials are not indicated for WNV infection, which is viral and self-resolving without clinical disease manifestation. WNV management in pigs generates zero antimicrobial use and no selection pressure for resistance.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific antiviral treatments exist for WNV infection in any species. In pigs, treatment is not needed because infection is subclinical and self-resolving. Infected pigs seroconvert and clear viremia without developing clinical disease requiring intervention. This contrasts with WNV infection in humans and horses, where neurological disease can occur and supportive care may be required—but even in those species, no specific therapeutics alter disease course.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No WNV vaccines are available for use in pigs. Several veterinary vaccines are commercially available for horses, including inactivated whole virus vaccines (WN Innovator, Vetera WNV, Prestige WNV) and a live canarypox-vectored vaccine expressing WNV prM and Env genes (Recombitek Equine WNV). An inactivated vaccine was authorized for geese in Israel, and a conditionally licensed vaccine exists for alligators in the United States. However, given that WNV infection in pigs is subclinical with no production impact, there is no commercial justification for developing pig-specific vaccines. The absence of vaccines for pigs reflects lack of need rather than technical barriers—the equine vaccine platforms could theoretically be adapted, but market demand does not exist.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
WNV has been endemic throughout the United States since its 1999 introduction and eradication is not feasible. The virus is maintained in transmission cycles involving at least 60 mosquito species, over 300 bird species, and numerous other vertebrate hosts—an extraordinarily broad ecological footprint that cannot be eliminated through any practical intervention. WNV circulates continuously through wildlife-mosquito cycles across virtually every US state. Sustained mosquito control sufficient to interrupt transmission would be technically impossible and prohibitively expensive across the continental scale required. No country has successfully eradicated WNV once established. The virus will remain a permanent feature of the North American arboviral landscape. For pigs specifically, eradication is irrelevant since infection causes no disease—the management goal is human and equine protection through mosquito control and targeted vaccination of horses, not elimination of pig exposure.